Background Tuberculosis preventive therapy (TPT) reduces TB-related morbidity and
mortality in people living with HIV (PLHIV). Cascade-of-care analyses help identify gaps and …

Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …

Tuberculosis (TB) remains a leading cause of morbidity and mortality among people living
with HIV. HIV-associated TB disproportionally affects African countries, particularly …

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), continues to pose a
major public health problem and is the leading cause of mortality in people infected with …

Macrocyclic compounds, characterized by cyclic structures, often originate from either
modified forms of unicyclic canonical molecules or natural products. Within the field of …

Women are significantly more likely to develop tuberculosis (TB) disease within the first 90
days after pregnancy than any other time in their lives. Whether pregnancy increases risk of …

Introduction Management of concomitant use of ART and TB drugs is difficult because of the
many drug–drug interactions (DDIs) between the medications. This systematic review …

Background Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent
use of rifampicin and protease inhibitors. We investigated whether dose escalation of …

Importance New data and new antiretroviral drugs and formulations continue to become
available for the prevention and management of HIV infection. Objective To provide updated …

People living with HIV have a higher risk of developing tuberculosis, and tuberculosis is one
of the leading causes of death among people living with HIV globally. Treating HIV and …